High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia

Leukemia Research

Volumn 35, Issue 12, 2011, Pages 1585-1590

  Kühnl, Andrea ^a   Kaiser, Martin ^a   Neumann, Martin ^a   Fransecky, Lars ^a   Heesch, Sandra ^a   Radmacher, Michael ^b   Marcucci, Guido ^b   Bloomfield, Clara D ^b   Hofmann, Wolf Karsten ^c   Thiel, Eckhard ^a   Baldus, Claudia D ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Acute myeloid leukemia; Chemoresistance; IGFBP2

Indexed keywords

ANTHRACYCLINE; CYTARABINE; MESSENGER RNA; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 2;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ADVERSE OUTCOME; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER RESISTANCE; CLINICAL PROTOCOL; COHORT ANALYSIS; CONTROLLED STUDY; DRUG MEGADOSE; ERG GENE; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; HOXA9 GENE; HOXB3 GENE; HUMAN; HUMAN CELL; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MALE; MEIS1 GENE; MOLECULARLY TARGETED THERAPY; MYB GENE; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; THERAPY RESISTANCE; TUMOR GENE; WT1 GENE;

ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; SIGNAL TRANSDUCTION; SOMATOMEDINS; UP-REGULATION; YOUNG ADULT;

EID: 80055102443     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.08.006     Document Type: Article

References (49)

1. Rowe J.M., Tallman M.S. How I treat acute myeloid leukemia. Blood 2010, 116:3147-3156.
2. LeRoith D., Roberts C.T. The insulin-like growth factor system and cancer. Cancer Lett 2003, 195:127-137.
3. Shimon I., Shpilberg O. The insulin-like growth factor system in regulation of normal and malignant hematopoiesis. Leuk Res 1995, 19:233-240.
4. Doepfner K.T., Spertini O., Arcaro A. Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway. Leukemia 2007, 21:1921-1930.
5. Baier T.G., Jenne E.W., Blum W., Schonberg D., Hartmann K.K. Influence of antibodies against IGF-I, insulin or their receptors on proliferation of human acute lymphoblastic leukemia cell lines. Leuk Res 1992, 16:807-814.
6. Chapuis N., Tamburini J., Cornillet-Lefebvre P., Gillot L., Bardet V., Willems L., et al. Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody. Haematologica 2009, 95:415-423.
7. Pollak M.N., Schernhammer E.S., Hankinson S.E. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004, 4:505-518.
8. Hoeflich A., Reisinger R., Lahm H., Kiess W., Blum W.F., Kolb H.J., et al. Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or promoter?. Cancer Res 2001, 61:8601-8610.
9. Wex H., Vorwerk P., Mohnike K., Bretschneider D., Kluba U., Aumann V., et al. Elevated serum levels of IGFBP-2 found in children suffering from acute leukaemia is accompanied by the occurrence of IGFBP-2 mRNA in the tumour clone. Br J Cancer 1998, 78:515-520.
10. Dawczynski K., Steinbach D., Wittig S., Pfaffendorf N., Kauf E., Zintl F. Expression of components of the IGF axis in childhood acute myelogenous leukemia. Pediatr Blood Cancer 2008, 50:24-28.
11. Bubendorf L., Kolmer M., Kononen J., Koivisto P., Mousses S., Chen Y., et al. Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. J Natl Cancer Inst 1999, 91:1758-1764.
12. Hattori H., Matsuzaki A., Suminoe A., Koga Y., Tashiro K., Hara T. Identification of novel genes with prognostic value in childhood leukemia using cDNA microarray and quantitative RT-PCR. Pediatr Hematol Oncol 2006, 23:115-127.
13. Dawczynski K., Kauf E., Schlenvoigt D., Gruhn B., Fuchs D., Zintl F. Elevated serum insulin-like growth factor binding protein-2 is associated with a high relapse risk after hematopoietic stem cell transplantation in childhood AML. Bone Marrow Transplant 2006, 37:589-594.
14. Vorwerk P., Mohnike K., Wex H., Rohl F.W., Zimmermann M., Blum W.F., et al. Insulin-like growth factor binding protein-2 at diagnosis of childhood acute lymphoblastic leukemia and the prediction of relapse risk. J Clin Endocrinol Metab 2005, 90:3022-3027.
15. Dohner H., Estey E.H., Amadori S., Appelbaum F.R., Buchner T., Burnett A.K., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115:453-474.
16. European Leukemia Net. European Leukemia Trial Registry. http://www.leukemia-net.org/content/leukemias/aml/aml_trials/database/.
17. Thiede C., Steudel C., Mohr B., Schaich M., Schakel U., Platzbecker U., et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002, 99:4326-4335.
18. Thiede C., Koch S., Creutzig E., Steudel C., Illmer T., Schaich M., et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 2006, 107:4011-4020.
19. Baldus C.D., Thiede C., Soucek S., Bloomfield C.D., Thiel E., Ehninger G. BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications. J Clin Oncol 2006, 24:790-797.
20. Blau O., Hofmann W.K., Baldus C.D., Thiel G., Serbent V., Schumann E., et al. Chromosomal aberrations in bone marrow mesenchymal stroma cells from patients with myelodysplastic syndrome and acute myeloblastic leukemia. Exp Hematol 2007, 35:221-229.
21. Marcucci G., Baldus C.D., Ruppert A.S., Radmacher M.D., Mrozek K., Whitman S.P., et al. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol 2005, 23:9234-9242.
22. Whitman S.P., Maharry K., Radmacher M.D., Becker H., Mrozek K., Margeson D., et al. FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood 2010, 116:3622-3626.
23. Faber J., Krivtsov A.V., Stubbs M.C., Wright R., Davis T.N., van den Heuvel-Eibrink M., et al. HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood 2009, 113:2375-2385.
24. Jin S., Zhao H., Yi Y., Nakata Y., Kalota A., Gewirtz A.M. c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis. J Clin Invest 2010, 120:593-606.
25. Kumar A.R., Li Q., Hudson W.A., Chen W., Sam T., Yao Q., et al. A role for MEIS1 in MLL-fusion gene leukemia. Blood 2009, 113:1756-1758.
26. Juric D., Lacayo N.J., Ramsey M.C., Racevskis J., Wiernik P.H., Rowe J.M., et al. Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias. J Clin Oncol 2007, 25:1341-1349.
27. Baldus C.D., Burmeister T., Martus P., Schwartz S., Gokbuget N., Bloomfield C.D., et al. High expression of the ETS transcription factor ERG predicts adverse outcome in acute T-lymphoblastic leukemia in adults. J Clin Oncol 2006, 24:4714-4720.
28. Huang A.M., Montagna C., Sharan S., Ni Y., Ried T., Sterneck E. Loss of CCAAT/enhancer binding protein delta promotes chromosomal instability. Oncogene 2004, 23:1549-1557.
29. Welch C., Santra M.K., El-Assaad W., Zhu X., Huber W.E., Keys R.A., et al. Identification of a protein, G0S2, that lacks Bcl-2 homology domains and interacts with and antagonizes Bcl-2. Cancer Res 2009, 69:6782-6789.
30. Kharas M.G., Yusuf I., Scarfone V.M., Yang V.W., Segre J.A., Huettner C.S., et al. KLF4 suppresses transformation of pre-B cells by ABL oncogenes. Blood 2007, 109:747-755.
31. Fernandez-Zapico M.E., Mladek A., Ellenrieder V., Folch-Puy E., Miller L., Urrutia R. An mSin3A interaction domain links the transcriptional activity of KLF11 with its role in growth regulation. Embo J 2003, 22:4748-4758.
32. Schwable J., Choudhary C., Thiede C., Tickenbrock L., Sargin B., Steur C., et al. RGS2 is an important target gene of Flt3-ITD mutations in AML and functions in myeloid differentiation and leukemic transformation. Blood 2005, 105:2107-2114.
33. El-Naggar A.A., Mahmoud B.F., Abou Shamaa L.A., Salama M.A. Changes of serum growth factors (IGF-I & IGFBP-2) and prediction of response to chemotherapy in patients with acute myeloid leukemia. Egypt J Immunol 2008, 15:73-80.
34. Elmlinger M.W., Sanatani M.S., Bell M., Dannecker G.E., Ranke M.B. Elevated insulin-like growth factor (IGF) binding protein (IGFBP)-2 and IGFBP-4 expression of leukemic T-cells is affected by autocrine/paracrine IGF-II action but not by IGF type I receptor expression. Eur J Endocrinol 1998, 138:337-343.
35. Kroon E., Krosl J., Thorsteinsdottir U., Baban S., Buchberg A.M., Sauvageau G. Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. Embo J 1998, 17:3714-3725.
36. Thorsteinsdottir U., Kroon E., Jerome L., Blasi F., Sauvageau G. Defining roles for HOX and MEIS1 genes in induction of acute myeloid leukemia. Mol Cell Biol 2001, 21:224-234.
37. Bentov I., LeRoith D., Werner H. The WT1 Wilms' tumor suppressor gene: a novel target for insulin-like growth factor-I action. Endocrinology 2003, 144:4276-4279.
38. Garg M., Moore H., Tobal K., Liu Yin J.A. Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia. Br J Haematol 2003, 123:49-59.
39. Paschka P., Marcucci G., Ruppert A.S., Whitman S.P., Mrozek K., Maharry K., et al. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol 2008, 26:4595-4602.
40. Heesch S., Goekbuget N., Stroux A., Tanchez J.O., Schlee C., Burmeister T., et al. Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia. Haematologica 2010, 95:942-949.
41. Saito Y., Kitamura H., Hijikata A., Tomizawa-Murasawa M., Tanaka S., Takagi S., et al. Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci Transl Med 2010, 2:17-19.
42. Virappane P., Gale R., Hills R., Kakkas I., Summers K., Stevens J., et al. Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2008, 26:5429-5435.
43. Yasunaga J., Taniguchi Y., Nosaka K., Yoshida M., Satou Y., Sakai T., et al. Identification of aberrantly methylated genes in association with adult T-cell leukemia. Cancer Res 2004, 64:6002-6009.
44. Potapova A., Hasemeier B., Romermann D., Metzig K., Gohring G., Schlegelberger B., et al. Epigenetic inactivation of tumour suppressor gene KLF11 in myelodysplastic syndromes. Eur J Haematol 2010, 84:298-303.
45. Kühnl A., Gökbuget N., Stroux A., Burmeister T., Neumann M., Heesch S., et al. High BAALC expression predicts chemoresistance in adult B-precursor acute lymphoblastic leukemia. Blood 2010, 115:3737-3744.
46. Liddiard K., Hills R., Burnett A.K., Darley R.L., Tonks A. OGG1 is a novel prognostic indicator in acute myeloid leukaemia. Oncogene 2010, 29:2005-2012.
47. Tavernier-Tardy E., Cornillon J., Campos L., Flandrin P., Duval A., Nadal N., et al. Prognostic value of CXCR4 and FAK expression in acute myelogenous leukemia. Leuk Res 2009, 33:764-768.
48. Hou H.A., Chou W.C., Lin L.I., Tang J.L., Tseng M.H., Huang C.F., et al. Expression of angiopoietins and vascular endothelial growth factors and their clinical significance in acute myeloid leukemia. Leuk Res 2008, 32:904-912.
49. Thomas X., Campos L., Mounier C., Cornillon J., Flandrin P., Le Q.H., et al. Expression of heat-shock proteins is associated with major adverse prognostic factors in acute myeloid leukemia. Leuk Res 2005, 29:1049-1058.